Streptomycin injectable manufacturers & suppliers

Streptomycin Injectable

Form: Injectable (IV/IM)

Strength: 1 g/2 mL, 2 g/2 mL

Reference Brands: no specific brands- Generics only

Category: Antibiotics

Streptomycin injectable is approved in the EU and US for treating tuberculosis and serious bacterial infections. In the EU, brands are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval depends on comprehensive clinical data, with generic formulations available. Both regions require detailed dossiers, including clinical trial results, manufacturing standards, and pharmacovigilance plans for approval and ongoing safety monitoring. Due to its critical role in combating MDR bacteria, strict prescribing controls and safety protocols are enforced. For regulatory support, dossier preparation, and compliance, visit PharmaTradz. We facilitate seamless market access consistent with European and US standards for safe, effective antibiotic therapy.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Colistin (Polymyxin E) Inhalation Solution (Nebulizer)

Strength: 75 mg/2 mL

Form: Inhalation Solution (Nebulizer)

Reference Brands: Coly-Mycin M(US)

View Details
Colistin (Polymyxin E)

Strength: 150 mg/5 mL, 300 mg/5 mL, 1.5 million IU/vial

Form: Injectable (IV/IM/SC)

Reference Brands: Coly-Mycin M(US)

View Details
Fosfomycin Oral Sachets Or Powder For Suspension

Strength: 3g in a sachet

Form: Oral Sachets or Powder for Suspension

Reference Brands: Zyflo(US)

View Details
Fosfomycin Iv

Strength: 2 g, 4g per vial

Form: Intravenous (IV)

Reference Brands: Zyflo(US)

View Details

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

We use cookies to ensure you get the best experience. Learn more